Cosmo Bio Co., Ltd. AI Stock Analysis
Want to see JP:3386 full AI Analyst Report?
Cosmo Bio Co., Ltd. (3386) AI Stock Analysis
Cosmo Bio Co., Ltd.
(TSE/TYO:3386)
Cosmo Bio earns a moderate score. The dominant strength is an exceptionally conservative balance sheet with virtually no debt and consistently growing equity, backed by a recovery in operating and free cash flow. The key risk is sustained margin compression: operating profit and ROE have fallen sharply from 2021 peaks, and revenue growth alone has not restored profitability. Technicals are a drag, with the price below all major moving averages and a negative MACD pointing to a mild downtrend. Valuation provides some support, with a fair P/E of 18.9 and an attractive, well-covered 4.07% dividend yield that rewards patient income investors while the company works to stabilize margins.
Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.89B
- Dividend Yield
- 4.15%
- Average Volume (3M)
- 4,153
- Price to Earnings (P/E)
- 20.7
- Beta (1Y)
- 0.29
- Revenue Growth
- 7.17%
- EPS Growth
- 36.23%
- Country
- Japan
- Employees
- 182
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cosmo Bio Co., Ltd. Business Overview & Revenue Model
Company Description
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, speci...
Cosmo Bio Co., Ltd. Financial Statement Overview
Summary
Cosmo Bio's financial profile is anchored by a fortress balance sheet (score 78) with essentially no debt (debt/equity ~0.2%), steadily rising equity of ¥9.37 billion and growing total assets. This is offset by weak income statement trends (score 52): despite 4.4% revenue growth to ¥10.77 billion, gross margin has slipped from ~40% to ~34%, EBIT has collapsed from ¥1.05 billion in 2021 to ¥342 million, and ROE has fallen to ~3.6%. Cash flow (score 61) improved markedly, with operating cash flow rebounding to ¥595 million and free cash flow to ¥366 million, though history shows high volatility. Net: safety and liquidity are strong, but profitability and capital efficiency are deteriorating.
Income Statement
52NeutralBalance Sheet
78PositiveCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.27B | 10.77B | 10.04B | 9.34B | 9.55B | 9.23B |
| Gross Profit | 3.89B | 3.70B | 3.33B | 3.25B | 3.44B | 3.66B |
| EBITDA | 515.00M | 509.00M | 455.00M | 801.00M | 931.00M | 1.26B |
| Net Income | 328.00M | 336.00M | 262.00M | 442.00M | 517.00M | 737.00M |
Balance Sheet | ||||||
| Total Assets | 12.18B | 12.66B | 11.72B | 10.87B | 10.31B | 10.07B |
| Cash, Cash Equivalents and Short-Term Investments | 4.08B | 2.95B | 2.69B | 3.02B | 3.04B | 3.56B |
| Total Debt | 20.00M | 20.00M | 22.00M | 24.00M | 27.00M | 28.00M |
| Total Liabilities | 2.29B | 2.70B | 2.17B | 1.84B | 1.69B | 1.75B |
| Stockholders Equity | 9.30B | 9.37B | 8.97B | 8.45B | 8.05B | 7.79B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 366.00M | 25.00M | 636.00M | 180.00M | 507.00M |
| Operating Cash Flow | 0 | 595.00M | 241.00M | 736.00M | 284.00M | 648.00M |
| Investing Cash Flow | 0 | 43.00M | -217.00M | -758.00M | -291.00M | -145.00M |
| Financing Cash Flow | 0 | -283.00M | -479.00M | -201.00M | -236.00M | -420.00M |
Cosmo Bio Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Negative. The current price of 1204.00 is below the 20-day moving average (MA) of 1223.60, below the 50-day MA of 1240.44, and below the 200-day MA of 1250.41, indicating a bearish trend. The MACD of -8.26 indicates Positive momentum. The RSI at 34.76 is Neutral, neither overbought nor oversold. The STOCH value of 23.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3386.
Cosmo Bio Co., Ltd. Peers Comparison
Overall Rating
JP:457070Outperform
JP:338660Neutral
JP:497845Neutral
JP:489242Neutral
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | JPY 8.48B | 21.59 | ― | 0.66% | 7.10% | 17.17% | |
| 60Neutral | JPY 6.97B | 20.70 | ― | 4.15% | 7.17% | 36.23% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 11.75B | -24.37 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 5.08B | -6.32 | ― | ― | 214.65% | 22.18% | |
| 37Underperform | JPY 6.07B | -4.74 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3386 | Cosmo Bio Co., Ltd. | 1204.00 | -121.22 | -9.15% | |
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 910.00 | -502.94 | -35.60% | |
| JP:4892 | Cyfuse Biomedical K.K. | 503.00 | -67.00 | -11.75% | |
| JP:4978 | ReproCELL Inc. | 110.00 | -45.00 | -29.03% | |
| JP:7776 | CellSeed Inc. | 153.00 | -141.00 | -47.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
